Millions of people in the US and around the world receive drugs or treatments every year that they never actually take. A lot of prescriptions don’t lead to treatment, even when doctors are careful about what they do. This situation is known as prescription abandonment or primary non-adherence. This early gap in the care journey is bad for patients’ health, costs more than it should, and lowers the overall quality of healthcare.
IQVIA’s recent data reveals that 27% of new prescriptions in the U.S. remain unfilled. This is because some patients don’t pick them up, and some payers refuse to pay for them. According to Surescripts, almost 98 million new prescriptions were never picked up, and in one survey, 1 in 5 patients said that they had not filled a prescription, and 1 in 10 reported splitting or skipping doses because of the cost.
These early abandonment events are different from traditional non-adherence, which is when someone skips doses or stops therapy later. They show that someone didn’t even start treatment, which can have immediate clinical effects.
A doctor assumes that they have provided care when they write a prescription. But there is a vulnerable time between the prescription pad and the first dose when patients decide to forgo picking up the drug at the pharmacy and decline to start the therapy. This early abandonment is different from ongoing non-adherence and has its own set of causes and effects.
The most reliable predictor of abandonment is cost. Patients are less likely to fill prescriptions when they have to pay high co-pays and deductibles:
The IQVIA Institute for Human Data Science reported that 69% of patients do not fill their prescriptions when they have to pay more than $250.
Studies indicate that higher co-pays make it much more likely that people will stop taking their medicine. For example, people who paid $50 in co-pays were almost four times more likely to stop taking their medicine than people who paid $10 or less. Insulin and proton-pump inhibitors (PPIs) are two types of medications that have higher abandonment rates than other types. This is probably because they are expensive and require a long-term commitment.
Not all prescriptions make it to the patient without a hitch. Because of formulary restrictions, prior authorizations, or step therapy requirements, insurance companies can often refuse to cover prescriptions. This is a big reason why a lot of prescriptions don’t get filled.
Patients often don’t know how to get their medicine, especially if the instructions are hard to follow or they don’t know how much it will cost, what other options they have, or what pharmacies they can go to. Patients may stop taking a prescribed drug if they don’t understand why they’re taking it, its side effects, or if their insurance covers it.
People who live in rural areas or those with few doctors have even more problems. People stop taking their medications, even if they’re cheap or covered, because they can’t get to pharmacies easily.
Not starting prescribed therapy, especially for chronic or high-risk conditions, can have real clinical effects:
Primary non-adherence is different from later non-adherence (skipping a refill or stopping early) because it happens before the patient takes any medication. Providers can’t see it most of the time because:
But a lot of people don’t fill their prescriptions: about one in four new prescriptions go unfilled, and the rates are even higher for younger adults and people who don’t have enough insurance.
To close the therapy access gap, you need to keep an eye on things and take action, such as:
Solutions like Surescripts First-Fill Abandonment let care teams know when a prescription isn’t filled, so they can quickly reach out to fix any problems.
Systems that automatically follow up with patients by phone, text message, or apps can help clear up confusion, make costs clear, and encourage pickup.
Giving patients real-time cost estimates and signing them up for copay assistance or patient assistance programs makes it easier for them to pay and stay in treatment.
Connected workflows between providers, pharmacies, and support teams make sure that abandonment triggers coordinated action before gaps get bigger.
To improve real-world outcomes, it is important to know why patients stop therapy before the first dose. High abandonment rates aren’t random; they are caused by things like cost, coverage, confusion, and access problems that are easy to see. Healthcare systems can lower abandonment rates, improve adherence, and make sure that clinical decisions lead to actual, timely treatment by finding these barriers and using connected technology and patient support. The first step toward better health outcomes for patients, doctors, and health systems is not just writing a prescription, but making sure that the prescription becomes therapy.
MedMonk addresses primary non-adherence by supporting patients from the moment a prescription is written through to treatment initiation. Through dedicated patient support programs, MedMonk helps navigate insurance coverage, prior authorizations, copays and financial assistance, pharmacy coordination, and education, removing the practical and financial barriers that often stop patients before the first dose. By combining real-time insights with proactive outreach and financial navigation, MedMonk helps ensure prescriptions don’t stall on paper but translate into timely, affordable treatment for the patients who need it most.
One in ten people worldwide is living with a rare disease, yet patients wait an average of 4 to 7 years for a correct diagnosis. For millions of people living with rare diseases, this is where the journey begins, not with dramatic findings, but with subtle inconsistencies that don’t align with standard clinical algorithms.
Rare Disease Month often highlights the diagnostic odyssey, and for good reason, as delayed diagnosis carries a heavy emotional, financial, and clinical burden for patients and families. However, for manufacturers, patient services leaders, and specialty programs, diagnosis is not the final step; rather, it marks the start of a new and complex operational phase.
In rare disease care, diagnosis identifies the patient, but access execution determines whether treatment actually begins.
A disease is generally considered rare if it affects fewer than 1 in 2,000 people. Yet collectively, rare diseases are far from rare.
In ultra-rare and orphan therapies, each diagnosed patient represents more than a data point. They represent:
Losing even one patient in the approval funnel is not a rounding error. It materially affects patient outcomes, therapy initiation rates, and commercial performance.
Rare conditions often present with non-specific symptoms such as fatigue, pain, GI disturbances, and neurological complaints are often present. The symptoms may resemble those of common disorders with varying fluctuations and progression.
Once a patient is identified and therapy is prescribed, a different layer of complexity emerges:
This is where operational risk begins. Awareness is no longer the issue. Infrastructure is.
Across rare disease programs, the same access failure points repeatedly appear:
These are not clinical problems. They are workflow problems.And in rare disease care, workflow determines speed, and speed determines outcomes.
Patient Services and Access Leaders today are under increasing pressure to:
Rare disease programs cannot rely solely on empathetic navigation. They require structured, measurable, and operationally precise execution. Because in orphan and ultra-rare launches, access leakage compounds quickly.
Delays in access to treatment are not just administrative setbacks; they carry real psychological and financial consequences for patients and families.
Even after a diagnosis is confirmed and a therapy is prescribed, many patients with rare diseases face prolonged uncertainty as they navigate approvals, affordability programs, and speciality pharmacy coordination.
Studies show that patients frequently report:
Many patients abandon therapy before the first dispense due to financial barriers, administrative complexity, or prolonged approval timelines. For rare disease therapies, often classified as orphan drugs, costs can be substantial, and prior authorisation requirements can further extend the wait.
The most vulnerable point in rare disease care is not diagnosis. It is the gap between the prescription and the first dispense.
This gap often includes:
Every additional day in this window increases abandonment risk. For patients, this delay can mean disease progression. For manufacturers, it can mean missed initiation metrics and unstable launch curves.
Once a patient receives a diagnosis and a therapy is prescribed, the most critical phase begins: execution. Operational efficiency plays a crucial role in determining the prompt initiation of treatment or its delay due to administrative bottlenecks. For rare disease programs, even small inefficiencies can compound into measurable access gaps.
At Medmonk, we focus specifically on the operational layer that follows diagnosis, ensuring that prescriptions translate into timely therapy initiation.
Our support includes:
We reduce friction at every stage of the approval funnel, shortening the time between prescription and first dispense and protecting both patient outcomes and program performance.
On Rare Disease Day, we reflect on the long diagnostic journeys patients endure. However, in the care of rare diseases, time does not end with diagnosis.
Speed to therapy is not just a performance metric; it is deeply personal. Every delay between prescription and treatment initiation can mean continued progression, unmanaged symptoms, missed developmental milestones, or prolonged uncertainty for patients and families. For children, weeks can influence growth and development. For adults, delays can affect employment, financial stability, and long-term life planning. For caregivers, it often means extended emotional strain and ongoing instability.
The impact extends far beyond clinical parameters. It touches mental health, relationships, and quality of life. Even after a diagnosis provides clarity, patients remain in limbo if access barriers prevent treatment from starting.
Diagnosis is a milestone. But on Rare Disease Day, it is important to recognize that the true turning point is timely, uninterrupted access to therapy. In rare disease care, progress is measured not only by scientific innovation but also by how quickly a patient moves from prescription to first dose, restoring momentum, stability, and hope.
Rare diseases are individually uncommon, but collectively, they represent one of the most complex challenges in modern healthcare. More than 300 million people globally live with a rare disease. An estimated 25–30 million individuals in the United States suffer from rare diseases. However, biology alone does not define the complexity of managing rare diseases. It is defined by access.
In rare disease programs, specialty pharmacies are often viewed as the backbone of therapy distribution. They manage cold-chain logistics, navigate prior authorizations, support adherence, and coordinate high-complexity dispensing. For many therapies, they are indispensable.
But for manufacturers, the more important question is not whether specialty pharmacies are essential. The question is whether the access pathway around them is actually optimized.
Because in rare disease care, infrastructure alone does not guarantee speed-to-therapy. What determines performance is how effectively the surrounding ecosystem is managed from intake to approval to first dispense.
Rare disease therapies are among the most operationally demanding products in healthcare. They often involve high-cost biologics, enzyme replacement therapies, gene therapies, or other precision medicines that require restricted distribution, temperature-controlled handling, intensive payer review, and ongoing monitoring.
This is why specialty pharmacy infrastructure matters. They help ensure that therapies are dispensed safely, compliantly, and with the right patient support. They typically manage:
In that sense, specialty pharmacies are essential. But they do not control the entire access journey. They execute within payer rules, manufacturer program structures, documentation quality, and handoff processes that often sit outside their direct control.
That is where the real performance gap begins.
Even with a strong specialty pharmacy network in place, friction tends to appear in predictable operational points.
These often include:
None of these issues means the specialty pharmacy model is failing. They reflect the reality that specialty pharmacies are often managing dozens of programs at once while operating within highly variable payer rules and manufacturer requirements.
That creates inconsistency, especially in rare disease programs where every case carries outsized importance.
From the manufacturer perspective, one of the most significant challenges is not simply whether a patient was referred, but whether the case is truly progressing in a timely and coordinated way.
Common manufacturer blind spots include:
In ultra-rare and specialty launches, these are not minor operational inefficiencies. A single stalled case can materially affect therapy initiation metrics, patient experience, and launch performance.
That is why infrastructure alone is not enough. A manufacturer can have the right distribution model on paper and still lose valuable time if execution around the case is not tightly managed.
Specialty pharmacies are built to dispense and support therapy within a compliant structure. They are not designed to absorb every upstream and cross-functional failure that occurs across the access ecosystem.
They do not determine:
In other words, specialty pharmacies are essential to therapy fulfillment, but they cannot fully compensate for fragmented access execution upstream.
When the surrounding workflow is misaligned, the result is predictable:
Effective rare disease access requires more than dispensing capability. It requires alignment across every step that determines whether a patient can actually start therapy.
That includes:
When these steps are coordinated, specialty pharmacy infrastructure performs better. When they are fragmented, even the strongest distribution network struggles to deliver speed and consistency.
This is why access performance should be viewed as an orchestration challenge, not just a distribution function.
The real opportunity for manufacturers is not to replace specialty pharmacy infrastructure. It is to strengthen the execution layer around it.
That means building more discipline into:
This is the layer where unnecessary delays can often be prevented before they become stalled starts or lost patients.
Medmonk focuses on the execution layer that surrounds specialty pharmacy infrastructure.
That includes:
We strengthen the broader access pathway so that specialty pharmacy execution can happen with fewer preventable delays and less friction.
Specialty pharmacies are essential in rare disease care. But access performance is determined by how well the surrounding ecosystem is managed.
For manufacturers, the question is not just whether specialty pharmacy infrastructure exists. It is whether the access process around it is managed well enough to start therapy without avoidable delays. In rare disease care, speed-to-therapy depends not just on distribution, but on strong access coordination from start to finish.
The rising cost of prescription medications is a growing concern, especially for patients managing chronic or rare conditions. According to a recent study, nearly 1 in 3 Americans struggle to afford their medications, with specialty drugs often costing upwards of $10,000 to $100,000 per year. These high prices can force patients to skip doses or abandon treatment altogether, which can have severe consequences for their health.
Copay assistance programs have emerged as a crucial resource to help patients offset these costs, making expensive treatments more affordable. However, many patients are unaware of how to access these programs or navigate the complexities involved. This article will guide you through the different types of copay assistance available and provide practical steps to help ease the financial burden of high-cost medications, ensuring you receive the treatment you need without compromise.
Copay assistance programs are designed to help patients afford high-cost medications, particularly specialty drugs needed for chronic or rare conditions. These programs are primarily offered by pharmaceutical manufacturers, and they provide copay cards or coupons that can reduce out-of-pocket costs, sometimes as low as $5 per fill.
In addition to manufacturer programs, charitable organizations offer financial support, especially to underinsured or uninsured patients. Another form of assistance is Patient Assistance Programs (PAPs), which provide free or discounted medications to eligible patients based on income or insurance status.
By understanding and utilizing these resources, patients can significantly reduce their financial burden and ensure they receive the medications they need without delays.
Navigating the various types of copay assistance programs can be crucial in reducing the financial burden of specialty medications. Here’s a breakdown of the most common types:
Accessing copay assistance programs can be a straightforward process if you know where to start. Here’s a step-by-step guide to help patients leverage these resources:
By following these steps, patients can streamline the process of accessing copay assistance, reduce out-of-pocket costs, and ensure timely access to their prescribed therapies.
While copay assistance programs can significantly reduce costs, patients often face challenges in navigating them:
To overcome these challenges, it’s essential to stay proactive. Leveraging the support of speciality pharmacies can streamline appeals and provide the necessary documentation to insurers. Patients should be persistent with denied claims and gather supporting evidence to reapply if needed. Keeping detailed records and following up regularly with pharmacies and insurers can help ensure timely access to the needed medications.
At Medmonk, we are dedicated to removing the financial barriers that often prevent patients from accessing essential specialty medications. By working directly with pharmaceutical companies, we secure copay cards that can significantly lower out-of-pocket expenses. We handle every process step, from checking eligibility to submitting applications, ensuring patients receive financial assistance quickly and efficiently.
Beyond copay support, our integrated platform expedites prior authorizations by seamlessly connecting with pharmacy and provider billing systems. This reduces delays in insurance approvals, allowing patients to focus on their health. For those who don’t qualify for copay programs, we assist with Patient Assistance Programs (PAPs) and charitable grants, ensuring that even those with limited coverage can access their medications.
With our extensive network of pharmacies and infusion centres, Medmonk provides timely and efficient solutions, helping patients stay on their prescribed therapies. Contact Medmonk today to learn how we can support your access to life-saving treatments.
Patient support programs (PSPs) have evolved rapidly over the last decade, but 2026 marks a turning point towards a more patient centered ecosystem. Today, PSP’s are not merely focused on enrollment and adherence but are becoming intelligent access ecosystems. They are designed to remove friction, predict risk, and accelerate time to therapy while keeping the patient experience at the heart of care.
Advances in health technology, from artificial intelligence (AI), real-world data, interoperability, and automation, are reshaping how patient support programs operate today. As healthcare systems face rising costs, workforce shortages, and increasingly complex therapies, PSPs are now expected to do more than support patients; they must actively enable access, continuity, and outcomes.
With global digital health investment continuing to grow and specialty therapies becoming more prevalent, PSPs in 2026 are positioned as a critical bridge between patients, providers, payers, and manufacturers.
In 2026, PSPs are moving beyond basic personalisation toward predictive and preventative engagement. AI-driven models now identify patients at risk of abandonment, delays, or non-adherence before issues arise.
Instead of reacting to missed refills or disengagement, PSPs can trigger early interventions, adjusting communication, escalating cases, or coordinating benefits support in real time.
The industry-wide focus on speed to therapy is one of the most important changes in 2026. Delays caused by prior authorizations, benefit verification, specialty pharmacy handoffs, and financial barriers are still a big threat to patient outcomes.
Cutting down the time between getting a prescription and getting treatment is no longer just a nice-to-have but a key measure of PSP success.
Case managers are still the most important part of successful PSPs, but by 2026, they will have AI to help them instead of being buried in paperwork. Smart triaging tools help put patients who need the most help at the top of the list. This lets human teams focus on the areas where they can make the biggest difference.
This hybrid model does a better job of balancing better outcomes with lower operational costs. This is becoming more and more important as PSPs move into new areas and indications.
Health equity has gone from a goal to a reality. In 2026, PSPs are expected to actively address social determinants of health (SDoH). These include transportation, language barriers, lack of access to technology, health literacy, and financial instability.
Digital tools now let PSPs:
There is more focus on inclusive design, which is no longer an option. There is clear evidence that social determinants of health have a substantial and direct impact on adherence, persistence, and outcomes.
Wearables and remote monitoring tools continue to play a growing role in PSPs, particularly for chronic and specialty conditions. In 2026, these tools are less about raw data and more about actionable insights.
This data-driven approach strengthens both patient care and program accountability.
Fragmentation across EHRs, pharmacies, and payer systems has long slowed patient access. In 2026, interoperability is becoming a baseline expectation rather than a differentiator.
FHIR-based integrations, API-driven platforms, and secure data-sharing frameworks now allow PSPs to operate with a near real-time view of patient journeys. This reduces administrative burden, minimizes duplication, and improves coordination across the care ecosystem.
Emerging technologies, including blockchain-enabled audit trails, further enhance trust, transparency, and data integrity, especially in complex, multi-stakeholder PSP environments.
In 2026, patient education is flexible, tailored to each person, and focused on results. AI-powered platforms give patients the right information at the right time, based on their diagnosis, therapy stage, and preferences. Today’s patients are more informed and connected with their care. They want to be involved in getting the best treatment possible.
With the rise in health technology, patients can be assisted in their care journey with mobile applications, interactive onboarding, AI chatbots, and virtual assistants helping them at every step.
There has been a lot of progress, but there are still many problems to solve:
Data privacy and trust: Strict rules and oversight are necessary to safeguard sensitive patient data across connected systems.
Digital divide: Not all patients can use digital tools equally well, so we need to use both digital and human methods.
Change management: To add new technologies to existing workflows, all stakeholders need to be trained and on the same page.
Cost pressures: For long-term sustainability, it is still important to find a balance between innovation and affordability.
In 2026, the best PSPs will be those that put practical impact ahead of technology for its own sake.
Medmonk is helping define the next generation of patient support programs by focusing on what matters most: removing barriers, accelerating access, and improving real patient outcomes. By using smart data and practical experience, Medmonk helps patients at every step, from checking benefits and providing financial help to coordinating with pharmacies and keeping in touch. Its commitment to equity and speed to therapy ensures that no patient is left navigating complexity alone. Through close collaboration with providers, payers, and life sciences partners, Medmonk enables PSPs that are not only technologically advanced but also truly patient-centric.
The future of patient support isn’t just digital; it’s connected, predictive, and human-centered. You can learn more about our services at www.medmonk.com.
In the healthcare industry, people often view a prescription as the final step. For patients, it signals hope. For providers, it marks a clinical decision. But in reality, a prescription is frequently just the beginning of a far more complex journey, one where access barriers, administrative delays, and financial hurdles can prevent patients from ever starting treatment.
This disconnect between prescribing and actual therapy initiation is known as the access gap. It is one of the most critical yet under-addressed challenges in modern healthcare.
On paper, prescribing a therapy suggests that care has been delivered. However, in practice, many patients never receive the medication they’ve been prescribed or receive it weeks or months later, when outcomes may already be compromised.
The reasons are usually nonclinical. Instead, they sit at the intersection of insurance complexity, system fragmentation, affordability, and operational inefficiency. For many patients suffering from chronic, rare, or specialty conditions, this gap can be devastating, impacting disease progression and prognosis.
Prior authorizations (PAs) are one of the most common points of failure. Even when therapies are medically necessary, insurers may require:
These processes can delay treatment by weeks and, in some cases, lead to abandonment altogether.
People suffering from chronic and rare diseases are often seeking medical treatment, multiple diagnoses, and endless investigations for many years before they can get a confirmed diagnosis. They have already spent a lot of money before they can start treatment; hence, the cost of treatment is a significant burden.
For high-cost specialty therapies, this financial burden can make treatment inaccessible, forcing patients to delay, ration, or decline care.
Healthcare operates across disconnected systems:
Without a unified view of the patient journey, delays and handoff failures are inevitable. Patients find themselves navigating a maze beyond their comprehension.
Administrative work is increasingly overwhelming clinicians and care teams. Chasing approvals, coordinating pharmacies, and following up on access issues diverts time away from patient care and increases the risk that patients fall through the cracks.
The latest digital health solutions are helping reduce these administrative and operational challenges, but due to limited interoperability between different providers, they still exist.
The access gap causes emotional stress in addition to logistical and financial issues. Patients with serious diagnoses often go through:
The effects of putting off or delaying treatment are big:
For therapies that change or save lives, speed to therapy is not a measure; it is a requirement.
To close the access gap, people need to change how they think. Success is no longer determined by the number of prescriptions written, but by the patients who initiate and adhere to therapy.
This means:
Don’t just assume that access is there; plan for it.
Medmonk was built to address this exact challenge, ensuring that prescriptions translate into real, timely treatment. By combining intelligent access navigation with hands-on patient support, Medmonk helps remove the barriers that delay or derail therapy.
Rather than adding another layer of complexity, Medmonk simplifies the journey, connecting patients, providers, payers, and pharmacies into a more coordinated access experience. You can check our services at www.medmonk.com.
In today’s healthcare landscape, writing a prescription is no longer enough. True success lies in ensuring that patients can access, afford, and adhere to the therapies they need.
Closing the access gap requires collaboration technology and a relentless focus on patient experience. When access is treated as a core part of care, prescriptions finally become what they were always meant to be: the start of treatment, not the end of the story.
For decades, clinicians have largely discussed access to healthcare in terms of provider availability, hospital proximity, or treatment approval. Today, however, one of the most significant barriers to care is not solely medical. It is financial. And increasingly, financial access is becoming a digital health problem.
As healthcare systems grow more complex, patients must navigate not only diagnoses and treatments but also insurance rules, benefit designs, prior authorizations, copay programs, and rising out-of-pocket costs. Fragmented digital systems and the lack of integrated patient-support technology deeply link these financial barriers. As a result, financial access is no longer a back-office concern; it directly influences whether patients ever start or continue treatment.
Even when effective therapies exist, many patients never begin or are unable to continue their prescribed treatment. Financial barriers remain a key driver of this trend. The CDC reports that nearly 1 in 4 U.S. adults struggle to afford their prescription medications, and almost 20% delay or skip treatment due to cost concerns, even after a prescription is written. In 2021 alone, 8.2% of U.S. adults aged 18–64 reported not taking medications as prescribed because of cost, including skipping doses or delaying refills.
Administrative hurdles further compound the problem: a nationwide physician survey found that 94% of doctors report prior authorization requirements delay patient care, often contributing to worse outcomes and the abandonment of needed therapies. Other research shows that these authorization burdens can directly result in delayed or discontinued treatment.
For patients, the financial journey often follows a familiar pattern:
These delays are rarely visible in traditional clinical data, but they are decisive in determining whether care actually happens.
Healthcare financing has evolved faster than the systems designed to support it. Many processes that determine affordability remain manual, fragmented, and opaque, forcing patients and care teams to rely on:
Patients navigate high-stakes decisions without clarity or real-time support in the absence of digital tools that connect financial data to the clinical journey. In this environment, financial access becomes inseparable from digital capability.
Financial data is scattered across multiple stakeholders:
Failure to communicate between these systems results in gaps for patients. A delay in benefit verification can stall therapy. A lack of visibility into copay support can result in unexpected bills. Each delay compounds the risk of abandonment. Digital health platforms that do not integrate financial access into the patient journey unintentionally contribute to these drop-offs.
In many conditions, especially rare diseases, oncology, and immune-mediated disorders, time to therapy is critical. Delays can lead to disease progression, increased hospitalizations, and reduced treatment effectiveness.
Yet much of this delay is driven not by clinical uncertainty, but by:
Improving speed to therapy requires digital systems that surface financial barriers early, automate workflows, and guide patients through available support options before delays occur.
From the patient’s perspective, affordability is not abstract—it is deeply personal. Unclear costs create anxiety, erode trust, and reduce engagement with care. When patients do not understand what they will owe and what financial support options exist, they are far more likely to disengage. Digital health solutions that focus only on clinical data miss a critical opportunity. True patient-centered care must include financial transparency, navigation, and reassurance.
As healthcare shifts toward value-based models and patient-centric design, financial navigation is emerging as a core component of care delivery. This includes:
Delivering these capabilities depends on interoperable digital infrastructure and patient-support platforms designed specifically to address financial access.
Modern digital health platforms uniquely position themselves to address this challenge. By integrating financial workflows directly into the care journey, they can:
Financial access is no longer a secondary concern; it is a frontline determinant of health and one that digital health must actively address.
MedMonk exists to ensure that prescriptions don’t stall at approval but translate into timely, affordable treatment. Through its patient support programs, MedMonk helps patients navigate insurance complexity, prior authorizations, benefit verification, and copay or financial assistance, addressing the most common reasons therapies are delayed or abandoned. By combining digital workflows with proactive, human-centered support, MedMonk accelerates speed to therapy, reduces financial barriers, and helps patients start and stay on treatment when it matters most.